Dapagliflozin review found changes in some diabetes-related kidney markers
In patients with diabetic kidney disease, dapagliflozin lowered some laboratory markers versus controls. A urine marker remained uncertain, and the abstract does not establish long-term kidney outcomes.
Based on the published abstract. The full paper may contain additional methods, results and limitations.
The 30-second takeaway
Among patients with diabetic kidney disease, dapagliflozin was associated with lower blood creatinine and HbA1c, a blood sugar marker, compared with controls. The urine albumin-to-creatinine ratio showed no statistically clear change, while low blood sugar episodes were less frequent. These findings concern measured markers and adverse events, rather than demonstrated prevention of kidney failure.
Some reported statistical results are internally inconsistent. The evidence combines a randomized trial with a comparative study, and the abstract omits follow-up duration and control treatments, limiting conclusions about longer-term kidney outcomes.
The outcomes were mainly markers
The review assessed blood creatinine, HbA1c and urinary albumin relative to creatinine. These are laboratory measurements. The abstract does not report kidney failure, survival or another clinical endpoint showing whether the marker changes translated into patient benefits.
The uncertain urine result
The urine albumin-to-creatinine comparison did not establish a clear treatment difference. This is uncertainty rather than proof of no effect. Fewer low blood sugar episodes were reported, but that result does not describe every possible adverse event.
The original publication
Efficacy and outcomes of dapagliflozin in diabetic nephropathy: A systematic review and meta-analysis.
Dahal K, Rawal L, Shah S et al.
Medicine (Baltimore) · 2025
- PubMed ID
- 40629621
- Record checked
AI-assisted research and writing. This explains one selected publication; it is not a complete review of everything known. Our approach.
One more question, understood.
Keep track of the research you’ve explored.